ArticleDiabetology & metabolic syndrome2025
Exploration of the potential therapeutic benefits of naringenin against diabetic retinopathy through a National comprehensive cross-sectional study and in vitro experiments.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between inflammatory biomarkers and cataracts: validation from the NHANES database and clinical studies.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDiabetic retinopathy (DR) is a severe, vision-threatening complication of diabetes. Despite the implementation of various preventive measures, controlling and preventing DR remains a significant challenge. This study investigates the association between naringenin (NAR) intake and the risk of DR.
methodsData were collected from the National Health and Nutrition Examination Survey (NHANES), and binary logistic regression analysis was used to examine the relationship between NAR consumption and DR after adjusting for multiple confounding variables. Additionally, biological experiments, such as CCK8, Western blot and Flow cytometry analysis, were conducted to elucidate the potential mechanisms underlying NAR's protective effects.
resultsThe results revealed that higher NAR consumption was associated with a reduced risk of DR, particularly in subgroups with diabetes duration exceeding 10 years. In vitro experiments revealed that high-glucose (HG) conditions significantly decreased the viability of human retinal microvascular endothelial cells (HRMECs). However, NAR administration mitigated these adverse effects. Western blot analysis showed that HG conditions markedly increased the expression of cleaved-Caspase-3 and Bax while decreasing Bcl-2 expression; these changes were reversed by NAR treatment. Flow cytometry analysis further confirmed that NAR significantly alleviated the increased apoptosis rate of HRMECs under HG conditions.
conclusionIn conclusion, NAR intake may benefit DR prevention by protecting retinal vascular endothelial cells from hyperglycemia-induced injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.